Rainmed Medical Launches caIMR System, Pioneering Precision Diagnosis of Coronary Microcirculation

Most patients with coronary heart disease exhibit varying degrees of coronary microvascular dysfunction (CMVD). To improve patient prognosis, measurement of the index of microcirculatory resistance (IMR) is equally indispensable.

Runmaide caIMR has pioneered a breakthrough over the limitations of traditional wire-based IMR assessment, providing a more practical clinical tool for evaluating coronary microcirculation. Conventional wire-based IMR measurement requires vasodilators and repeated saline injections, resulting in prolonged procedure times and higher surgical risks; therefore, it has been limited to clinical research applications. In contrast, caIMR does not require a pressure wire or vasodilators, nor does it necessitate changes to the operator’s procedural habits. By leveraging angiographic images, TIMI flow grade, real-time aortic pressure, and optimized computational fluid dynamics algorithms, caIMR can calculate the IMR value within an average of 5 minutes. This approach is safer, more efficient, and simpler, creating new opportunities for the large-scale clinical adoption of coronary microcirculation assessment.

VCBeat Selects New Product Review, Issue 14, InvitesHuo Yunlong, a founding shareholder of Rainmed Medical,Liu Kangjian, Vice President and Board Secretary of Rainmed Medical; Liu Jian, Chief Physician at Peking University People's Hospital; and Wang Haiyan, Associate Chief Physician at the First Affiliated Hospital of Xi'an Jiaotong University, presented an introduction to Rainmed's products.

World’s First Non-Invasive IMR Measurement System

1. The world’s first non-invasive diagnostic product for microcirculatory lesions;

2. The world’s only non-invasive microcirculatory resistance index measurement system to have completed confirmatory clinical trials;

3. XiangThe IMR accuracy relative to the guidewire reaches as high as 93.81%, demonstrating excellent consistency, sensitivity, and specificity;

4. The world’s first non-invasive microcirculatory resistance index measurement system approved for commercialization.

Viewing Method: Scan the QR code on the poster below to add our assistant and reserve your spot for the live broadcast.

Huo YunDragon

Founding Shareholders of Rainmed Medical

Tenured Associate Professor and Doctoral Supervisor at the Institute of Mechanobiology, Shanghai Jiao Tong University; currently serves as an Editorial Board Member for *American Journal of Physiology-Heart and Circulatory Physiology* and a Guest Associate Editor for *Frontiers in Physiology*; has been invited to review manuscripts for more than 70 international academic journals. He has long been engaged in research on cardiovascular biomechanics, achieving significant results in hemodynamics, soft tissue mechanics of the myocardium and vascular walls, myocardial infarction, and heart failure.

Liu Kangjian

Vice President and Board Secretary of Runmaide Medical

Comprehensively responsible for corporate capital operations, strategic investments, external collaborations, and public relations, with extensive operational and management experience in medical technology companies. Previously served at the headquarters of China Mobile Group, overseeing technical management, network operations, and standard-setting, demonstrating a solid technical foundation. Subsequently held positions at several renowned investment institutions, where he invested in dozens of star technology projects, including those in the medical technology sector. With over 10 years of experience in investment, financing, and management, he has assisted numerous portfolio companies in completing financing, mergers and acquisitions, and initial public offerings (IPOs), possessing deep understanding and insight into the medical technology field.

Liu Jian

Chief Physician, Peking University People's Hospital

Professor, Doctoral Supervisor. Postdoctoral Fellow in Intravascular Ultrasound at Columbia University Medical Center/The Cardiovascular Research Foundation (USA); Deputy Director of the Department of Cardiology, Peking University People’s Hospital; Fellow of the American College of Cardiology (FACC), Fellow of the European Society of Cardiology (FESC), and Member of the Society for Cardiovascular Angiography and Interventions (SCAI); Vice Chairman and Secretary-General of the Committee on Cardiovascular Evidence-Based and Precision Medicine, Chinese Research Hospital Association; Vice Chairman of the Cardiovascular Professional Committee, Cross-Strait Medical and Health Exchange Association; Deputy Leader of the Coronary Intracoronary Imaging and Physiology Group, Chinese Society of Cardiology, Chinese Medical Association.

Wang Haiyan

Associate Chief Physician, The First Affiliated Hospital of Xi'an Jiaotong University

Deputy Director, Department of Structural Heart Disease; first and corresponding author of 15 SCI-indexed papers (cumulative Impact Factor: 54.34) and 1 EI-indexed paper; principal investigator for one National Natural Science Foundation of China grant and one Shaanxi Provincial Social Development Project; completed eight clinical trials; associate editor of one textbook and contributing author to three cardiovascular textbooks. Currently serves as Chairman of the Structural Heart Disease Subcommittee of the Xi’an Medical Association, Chairman of the Structural Heart Disease Branch of the Chinese Medical Association Xi’an Branch, Vice Chairman of the Shaanxi Provincial Heart Failure Committee, Standing Committee Member of the Shaanxi Provincial Pacing and Electrophysiology Committee, and Vice Chairman of the Young Cardiologists Committee of the Shaanxi Provincial Cardiovascular Medicine Society. Has served as conference chair and invited speaker at numerous national academic conferences, and has participated extensively in grassroots medical outreach programs and national-level healthcare services. Specializes in complex cardiovascular interventions, diagnosis and treatment of refractory cardiovascular diseases, and standardized management of chronic cardiovascular conditions.